Objective： To study the effects of Aidi Dripping Pills on immune functions of the tumor-bearing mouse on the basis of the previous experimental studies on its tumor-inhibiting and life-prolonging effects. Methods： B...Objective： To study the effects of Aidi Dripping Pills on immune functions of the tumor-bearing mouse on the basis of the previous experimental studies on its tumor-inhibiting and life-prolonging effects. Methods： By using the transplantation tumor mouse models, the effects of Aidi Dripping Pills on the lymphocyte transformation rate and the hemolysin formation in the Sis0 tumor-bearing mice, and on the phagocytic function of macrophages in the abdominal cavity of H22 tumor-bearing mice were investigated. Results： In the 2.25 g/kg and 1.125 g/kg Aidi Dripping Pills groups, the lymphocyte transformation rates in the Sis0 tumor-bearing mice were significantly higher than that of the control group （P〈0.01）. In all the Aidi Dripping Pills groups, HC50 significantly increased （P〈0.01 or P〈0.05）, carbon granular clearance significantly raised, and both the phagocytic index and phagocytic coefficient were significantly higher than those in the control group （P〈0.01 or P〈0.05）. Conclusion： The Aidi Dripping Pills can significantly increase the cellular immune function, the humoral immune function and the phagocytic function of the mononuclear- macrphages, so it may show anti-tumor effects by enhancing the function of the reticuloendothelial system.展开更多
Objective: To investigate the effects of Aidi Injection (艾迪注射液 ADI) on the MicroRNAs (miRNA) expression profiles in human breast cancer cells and explore the potential targets of the cancer treatment. Methods: MC...Objective: To investigate the effects of Aidi Injection (艾迪注射液 ADI) on the MicroRNAs (miRNA) expression profiles in human breast cancer cells and explore the potential targets of the cancer treatment. Methods: MCF-7 breast cancer cells were grown in RPMI 1640 medium supplemented with different concentrations of ADI. The inhibition of cell proliferation was measured by MTT assay. MCF-7 cells were treated by ADI with above 50% inhibiting concentration (IC50) for 48 h. The expression profiles of miRNA in ADI-treated and ADI-untreated MCF-7 cells were detected with miRNA microarray chips and the array data were verified by quantitative RT-PCR. MCF-7 cells were transiently transfected with miRNA mimics by liposome method. Potential mRNA targets were predicted by informatics analysis with TargetScan and PicTar software. Results: ADI significantly inhibited the proliferation of MCF-7 cells in a dose-dependent manner. The IC50 of ADI was 55.71 mg/mL after treatment for 48 h. The 60 mg/mL ADI was used as the therapeutic drug concentration. Microarray analysis identified 45 miRNAs that were up-regulated and 55 miRNAs that were down-regulated in response to ADI treatment. Many ADI-induced miRNAs were related to breast cancers. The microarray data were validated by qRT-PCR. Ectopic expression of 100 nmol/L mir-126 mimics significantly inhibited the proliferation of MCF-7 cells. The 12 potential target genes of mir-126 were predicted by both TargetScan and PicTar software. Conclusions: The miRNA may serve as therapeutic targets, and the modulation of miRNA expression is an important mechanism of ADI inhibiting breast cancer cell growth.展开更多
OBJECTIVE: To conduct a Meta-analysis of studies on the effect of Aidi injectioncombined with chemotherapy versus chemotherapy alone in the treatment of gastric cancer(GC).METHODS: Nine electronic databases and six gr...OBJECTIVE: To conduct a Meta-analysis of studies on the effect of Aidi injectioncombined with chemotherapy versus chemotherapy alone in the treatment of gastric cancer(GC).METHODS: Nine electronic databases and six gray literature databases were comprehensively searcheduntil April 20,2013. Two reviewers independently selected and assessed included trialsaccording to the inclusion and exclusion criteria. The risk of bias tool from the Cochrane Handbook version 5.1.0was used to assess trial quality. All calculations were performed using Review Manager 5.0.RESULTS: Thirty-two studies including 1927 participants met the inclusion criteria,most of which were low quality. Compared with chemotherapy alone,Aidi injection plusthe same chemotherapy significantly improved the effective rate [OR = 1.52,95% CI(1.24,1.86),P < 0.0001],clinical beneficial rate [OR = 1.77,95% CI(1.33,2.36),P < 0.0001],and quality of life [OR = 3.02,95% CI(2.39,3.82),P <0.000 01]. There was a significant improvement in nausea and vomiting incidence [OR = 0.34,95%CI(0.24,0.47),P < 0.000 01],diarrhea [OR = 0.47,95%CI(0.33,0.69),P < 0.000 01],leukopenia( 3,0.51),P = 0.05],hemⅢ-ogⅣ)[OR = 0.34,95%CI(0.2lobin decrease(thromⅢ-boⅣ) [OR = 0.42,95%CI(0.18-1.00),P = 0.05],cytopenia(4],and Ⅲ-damⅣ) [OR = 0.46,95%CI(0.22,0.96),P = 0.0age to liver function [OR = 0.36,95%CI(0.24,0.54),P < 0.000 01].CONCLUSION: Aidi injection combined with chemotherapy significantly improved the clinical effect of chemotherapy,reducing the incidence of adverse events. Use of the CONSORT statement for randomized controlled trials is recommended for stricter reporting.展开更多
OBJECTIVE:To assess the efficacy and safety of Aidi injection plus transarterial chemoembolization(TACE)in patients with primary hepatic carcinoma.METHODS:A comprehensive research of seven electronic databases was per...OBJECTIVE:To assess the efficacy and safety of Aidi injection plus transarterial chemoembolization(TACE)in patients with primary hepatic carcinoma.METHODS:A comprehensive research of seven electronic databases was performed for comparative studies evaluating Aidi injection combined with TACE for primary hepatic carcinoma until September 2016.Two authors independently extracted data and assessed the methodological quality of the included trials using the Cochrane risk of bias tool from the Cochrane Handbook version 5.1.0.Data was synthesized by using Rev Man 5.3 software.RESULTS:Forty-nine studies involving 3435 patients met the inclusion criteria,most of which were low methodological quality.Compared with TACE alone,Aidi injection plus TACE can significantly improve the efficiency rate[RR=1.33,95%CI(1.24,1.43),P<0.00001],clinical beneficial rate[RR=1.25,95%CI(1.17,1.33),P<0.00001],survival rate[6 months,RR=1.19,95%CI(1.09,1.29),P<0.0001],12 months,[RR=1.37,95%CI(1.24,1.52),P<0.00001],18 months,[RR=2.00,95%CI(1.26,3.20),P<0.004],24 months,[RR=1.44,95%CI(1.22,1.70),P<0.0001],36 months,[RR=1.50,95%CI(1.07,2.11),P=0.02<0.05],quality of life[RR=1.84,95%CI(1.64,2.05),P<0.00001]and immune function[CD3+,MD=11.12,95%CI(7.93,14.30),P<0.00001],CD4+,[MD=10.37,95%CI(7.29,13.45),P<0.00001],CD4+/CD8+,[MD=0.30,95%CI(0.07,0.53),P=0.01<0.05],NK,[MD=7.49,95%CI(6.64,8.34),P<0.00001].A significant improvement was also found in improvement of symptoms[RR=1.64,95%CI(1.38,1.94),P<0.00001],leukopenia[RR=0.60,95%CI(0.54,0.66),P<0.00001],thrombocytopenia[RR=0.46,95%CI(0.34,0.61),P<0.00001],nausea and vomiting incidence[RR=0.66,95%CI(0.54,0.81),P<0.0001),liver damage rate[RR=0.57,95%CI(0.42,0.77),P=0.0003<0.05),and kidney damage rate[RR=0.18,95%CI(0.05,0.68),P=0.01<0.05].CONCLUSION:The results suggested that Aidi injection plus TACE significantly improve the clinical effect of TACE,and reduce the incidence of adverse events.However,rigorous multicenter trials with larger size are warranted to further confirm the findings.展开更多
Objective:To explore the active ingredients and potential mechanism of Aidi injection in the treatment of hepatocellular carcinoma by network pharmacology.Methods:Traditional Chinese Medicine Systems Pharmacology Data...Objective:To explore the active ingredients and potential mechanism of Aidi injection in the treatment of hepatocellular carcinoma by network pharmacology.Methods:Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP)and Traditional Chinese Medicines Integrated Database(TCMID)were used to screen the active ingredients of four traditional Chinese medicines of Renshen,Huangqi,Ciwujia,and Banmao and corresponding potential targets.Screening of hepatocellular carcinoma-related targets through the Online Mendelian Inheritance in Man(OMIM)and GeneCards Suite(The Human Gene Database)database platforms.The drug and disease targets are merged to obtain the intersection,and the information is imported into Cytoscape 3.7.2 to construct a network diagram of the active ingredients of Aidi injection and related targets of hepatocellular carcinoma,and the topology analysis is performed.A protein-protein interaction(PPI)network was constructed and analyzed using the STRING online analysis platform.Uses the Database for Annotation,Visualization and Integrated Discovery(DAVID)to perform GO function enrichment analysis of targets and enrichment of KEGG pathways analysis.Results:A total of 33 potential active ingredients were screened from Aidi injection for treating hepatocellular carcinoma,including quercetin,kaempferol,beta-sitosterol,isorhamnetin and other important active ingredients.There are 106 potential targets for active ingredient action,6,677 disease-related targets,and 89 drug-disease common targets.Through the network diagram,it was found that the highest degree of target is PTGS1.In the PPI graph,a total of 87 nodes.Among them,the higher degree values include IL6,CASP3,VEGFA,MAPK8,JUN,EGFR,MYC,PTGS2 and FOS.A total of 60 related signal pathways were obtained by GO enrichment analysis.It mainly involves biological processes such as inhibiting abnormal proliferation and differentiation of hepatocellular carcinoma cells,inhibiting angiogenesis of hepatocellular carcinoma,regulating cell cycle and promoting apoptosis.KEGG pathway enrichment analysis screened a total of eight significantly different signal pathways.Among them,P53,VEGF,MAPK,Toll-like receptor,ErbB signaling pathways play an important role in treatment.Conclusion:This study initially revealed the potential mechanism of multi-component,multi-target and multi-pathway treatment of Aidi injection for hepatocellular carcinoma,and provided ideas for the subsequent verification of the molecular mechanism of Aidi injection for hepatocellular carcinoma.展开更多
Objective： To evaluate the effects of Aidi injection on vinorelbine plus cisplatin （NP） chemotherapy for advanced non-small cell lung cancer （NSCLC）. Methods： Ninety eight patients with advanced NSCLC were rando...Objective： To evaluate the effects of Aidi injection on vinorelbine plus cisplatin （NP） chemotherapy for advanced non-small cell lung cancer （NSCLC）. Methods： Ninety eight patients with advanced NSCLC were randomized to receive either NP alone or NP plus Aidi injection every 3 weeks. The primary endpoint was overall survival; secondary endpoints included overall response rate, time to progression, and safety. Results： The median overall survival time was 11.6 months in NP plus Aidi-treated patients and 10.1 months in NP alone-treated ones, and 1- and 2-year survival rates were higher in the former （47% and 22%） than the latter （42% and 15%）. The overall response rates in Aidi injection plus NP-treated patients tended to be higher but not statistically significant compared with NP alone-treated ones. The occurrence rates of grades 3 or 4 toxicities, e.g. fatigue, nausea, vomiting, appetite loss, leucopenia, thrombocytopenia and anemia, were lower in Aidi injec- tion plus NP-treated patients than NP alone-treated ones, although not significantly different between them. Con^lusion：Aidi injection promotes NP chemotherapeutic effects, reduces the toxicities, and improves the patients＇ tolerance to chemotherapy as well. It may be an effective adjunct to chemotherapy in patients with NSCLC.展开更多
Objective:To discuss the effect of Aidi injection-assisted intravenous chemotherapy on serum tumor markers and peripheral blood immune molecules in patients with colon cancer. Methods: 92 patients with colon cancer wh...Objective:To discuss the effect of Aidi injection-assisted intravenous chemotherapy on serum tumor markers and peripheral blood immune molecules in patients with colon cancer. Methods: 92 patients with colon cancer who were hospitalized in Deyang People's Hospital in Sichuan Province between October 2013 and October 2016 were collected and divided into the control group (n=50) who received intravenous chemotherapy alone and the observation group (n=42) who received Aidi injection-assisted intravenous chemotherapy after the therapies were reviewed. The differences in serum tumor markers and peripheral blood immune molecule contents before and after treatment were compared between two groups of patients.Results:Before treatment, differences in serum tumor marker levels and peripheral blood immune molecule levels were not statistically significant between two groups of patients. After treatment, serum tumor markers CEA, CA199, CA50, PTN and CCSA-2 levels of observation group were lower than those of control group, peripheral blood Th1/Th2 cytokines IL-2 and IFN-γ levels were higher than those of control group while IL-4 and IL-10 levels were lower than those of control group, and peripheral blood Th17 cytokines IL-17A and IL-22 levels were lower than those of control group.Conclusion: Aidi injection-assisted intravenous chemotherapy can effectively reduce the serum tumor marker contents and optimize the immune molecule levels in patients with colon cancer.展开更多
Objective:To study the effect of Aidi injection combined with FOLFOX4 chemotherapy on tumor stem cell characteristics and antitumor immune response in patients with advanced colon cancer.Methods:Patients with advanced...Objective:To study the effect of Aidi injection combined with FOLFOX4 chemotherapy on tumor stem cell characteristics and antitumor immune response in patients with advanced colon cancer.Methods:Patients with advanced colon cancer who received chemotherapy in our hospital between May 2013 and June 2016 were selected and randomly divided into the combined chemotherapy group who received Aidi injection combined with FOLFOX4 chemotherapy and the FOLFOX4 group who received FOLFOX4 chemotherapy alone. After chemotherapy, the serum was collected to determine the levels of tumor markers, tumor lesions were collected to determine the expression of tumor stem cell markers and immune cell markers, and peripheral blood mononuclear cells were collected to determine the expression of immune cell markers.Results:After 2 and 4 cycles of treatment, serum CEA, CA199, CCSA-3 and CCSA-4 levels of combined chemotherapy group were significantly lower than those of FOLFOX4 group, and the mean fluorescence intensity of CD3, CD4, CD8, CD16 and CD56 in peripheral blood mononuclear cells were significantly higher than those of FOLFOX4 group;after four cycles of chemotherapy, CD133, Musashi-1, Piwil2, Nanog and Sox-2 protein content in tumor lesions were significantly lower than those of FOLFOX4 group, and the mean fluorescence intensity of CD3, CD4, CD8, CD16 and CD56 were significantly higher than those of FOLFOX4 group.Conclusion: Aidi injection combined with FOLFOX4 chemotherapy treatment of advanced colon cancer will help reduce the tumor load, inhibit tumor stem cell characteristics and enhance antitumor immune response.展开更多
Objective: To explore the influence of Aidi injection combined with paclitaxel and platinum drugs on malignant molecule expression in malignant ascites of patients with advanced gastric cancer. Methods: A total of 80 ...Objective: To explore the influence of Aidi injection combined with paclitaxel and platinum drugs on malignant molecule expression in malignant ascites of patients with advanced gastric cancer. Methods: A total of 80 patients with advanced gastric cancer complicated by malignant ascites who were treated in the hospital between January 2015 and December 2016 were divided into control group and observation group by random number table, each with 40 cases. Control group were treated with paclitaxel and platinum drugs, and observation group were treated with Aidi injection combined with paclitaxel and platinum drugs. The differences in the malignant molecule expression in malignant ascites were compared between the two groups of patients before and after treatment. Results: Before treatment, the proliferation, invasion and autophagy gene expression in malignant ascites were not statistically different between the two groups of patients. 1 week after treatment, EZH2, I2PP2A, Gal-1, HPA-1, MTA1, TROP2, BNIP3 and LC3 mRNA expression in malignant ascites of both groups of patients were lower than those before treatment while PTPN13, TRIM28, SOX7, Syndecan-1 and Beclin1 mRNA expression were higher than those before treatment, and EZH2, I2PP2A, Gal-1, HPA-1, MTA1, TROP2, BNIP3 and LC3 mRNA expression in malignant ascites of observation group were lower than those of control group while PTPN13, TRIM28, SOX7, Syndecan-1 and Beclin1 mRNA expression were higher than those of control group. Conclusion: Aidi injection combined with paclitaxel and platinum drugs can effectively inhibit the gastric cancer cell proliferation and invasion, and regulate cell autophagy activity in the malignant ascites of patients with advanced gastric cancer.展开更多
Objective: To evaluate the effects of Aidi Injection(艾迪注射液, AD) in combination with Western medical therapies(WMT) in patients with primary liver cancer(PLC). Methods: Randomized controlled trials(RCTs) comparing...Objective: To evaluate the effects of Aidi Injection(艾迪注射液, AD) in combination with Western medical therapies(WMT) in patients with primary liver cancer(PLC). Methods: Randomized controlled trials(RCTs) comparing AD plus WMT with WMT alone were retrieved from inception to March 2013 by retrieving the literature database thoroughly and systematically. The extracted data from included studies were analyzed and synthesized by Review Manager 5.2 software. The Cochrane risk of bias tool was used to assess the quality of included studies, and Begg’s and Egger’s tests were used to evaluate the potential presence of publication bias. The studies were divided into 7 separate subgroups in terms of quality of life(QOL), recent chemotherapy and the incidence of leukocyte reduction. The subgroup analysis was applied to assess the heterogeneity between included researches, and the sensitivity analysis was used to weigh the stability of studies. Results: Twenty-four RCTs were included in this study. Compared with WMT used alone, AD as additional intervention was more effective on improving QOL(P<0.01), increasing short-term efficacy(P<0.01), prolonging life(P<0.05 or P<0.01), relieving clinical symptoms(P<0.01), and reducing adverse events(e.g. reduce white blood cell counts, P=0.002;reduce in platelet counts, P<0.01). Subgroup analysis showed that the hepatic artery interventions with AD was superior in improving QOL(P<0.01) and enhancing short-term response rates(P=0.007) and reducing white blood cell counts(P=0.0004) than hepatic artery interventions alone(P<0.01). The chemoembolization plus AD or the chemotherapy plus AD were both better than chemoembolization or the chemotherapy alone in improving the QOL and short-term response rate(P<0.05 or P<0.01). Conclusions: AD in combination with WMT improves QOL in patients with PLC. Considering the inherent limitations of the included studies, further well-designed, rigorously performed, high-quality, and double-blinded RCTs with large sample sizes are needed.展开更多
Background： The aim of this study was to assess the efficacy and safety of vinorelbine and cisplatin （NP chemotherapy） alone or in combination with Aidi injection for the treatment of advanced nonsmall cell lung ca...Background： The aim of this study was to assess the efficacy and safety of vinorelbine and cisplatin （NP chemotherapy） alone or in combination with Aidi injection for the treatment of advanced nonsmall cell lung cancer （NSCLC）. Methods： Pertinent publications were identified in PubMed, EMBASE, Cochrane Library, CNKI, CQVIR and Wanfang databases, up to December 8, 2015. After quality assessment of all included randomized controlled trials evaluating Aidi injection combined with NP chemotherapy for the treatment of advanced NSCLC, a meta-analysis was performed by Review Manager 5.2 and STATA 12.0 for statistical analyses. Results： Twelve studies including 509 and 503 cases in the experimental and control groups, respectively, were finally analyzed. The meta-analysis revealed that when cisplatin dose ranging from 20 to 40 mg/m2, combination of Aidi injection and NP chemotherapy was statistically different compared with NP chemotherapy alone in enhancing efficiency （relative risk [RR] = 1.24, 95% confidence interval [C/] [ 1.05-1.47], P = 0.010） and reducing the incidence of Grade II or above nausea and vomiting （RR = 0.49, 95% CI [0.30-0.80], P = 0.005）. Meanwhile, with cisplatin ranging from 80 to 120 mg/m2, no significant differences in efficiency （RR = 1.11, 95% CI [0.87- 1.42], P = 0.390） and Grade II or above nausea and vomiting （RR = 0.88, 95% CI [0.71-1.10], P = 0.260） were obtained. In addition, Aidi injection combined with NP chemotherapy was superior to NP chemotherapy alone in improving the quality of life, alleviating Grade II or above leukopenia and thrombocytopenia. Conclusions： Aidi injection combined with NP chemotherapy can enhance efficiency, improve the quality of life, and decrease adverse effects in patients with advanced NSCLC.展开更多
Objective： To study the effect of Aidi Injection （艾迪注射液,ADI） applied in the bronchial artery infused （BAI） neo-adjuvant chemotherapy for stage ⅢA non-small cell lung cancer （NSCLC） before surgical operati...Objective： To study the effect of Aidi Injection （艾迪注射液,ADI） applied in the bronchial artery infused （BAI） neo-adjuvant chemotherapy for stage ⅢA non-small cell lung cancer （NSCLC） before surgical operation.Methods： The 60 patients with NSCLC stage ⅢA underwent two courses BAI chemotherapy before tumor incision were assigned to two groups,the treatment and the control groups,using a random number table,30 in each group.ADI （100 mL） was given to the patients in the treatment group by adding into 500 mL of 5% glucose injection for intravenous dripping once daily,starting from 3 days before each course of chemotherapy,and it lasted for 14 successive days,so a total of 28 days of administration was completed.The therapeutic effectiveness and the adverse reaction that occurred were observed,and the levels of T-lymphocyte subsets,natural killer cell activity,and interleukin-2 in peripheral blood were measured before and after the treatment.Results： The effective rate in the treatment group was higher than that in the control group （70.0% vs.56.7%,P〈0.05）.Moreover,as compared with the control group,the adverse reaction that occurred in the treatment group was less and mild,especially in terms of bone marrow suppression and liver function damage （P〈0.05）.Cellular immune function was suppressed in NSCLC patients,but after treatment,it ameliorated significantly in the treatment group,showing significant difference as compared with that in the control group （P〈0.05）.Conclusion： ADI was an ideal auxiliary drug for the patients in stage ⅢA NSCLC received BAI neo-chemotherapy before surgical operation;it could enhance the effectiveness of chemotherapy,ameliorate the adverse reaction and elevate patients＇ cellular immune function;therefore,it is worthy for spreading in clinical practice.展开更多
Objective：To investigate the efficacy of Aidi Injection（艾迪注射液） on overexpression of P-glycoprotein（P-gp） induced by vinorelbine and cisplatin（NP） regimen in patients with non-small cell lung cancer（NSCLC...Objective：To investigate the efficacy of Aidi Injection（艾迪注射液） on overexpression of P-glycoprotein（P-gp） induced by vinorelbine and cisplatin（NP） regimen in patients with non-small cell lung cancer（NSCLC）, and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. Methods：Totally 150 patients with NSCLC were randomly assigned to the control group, the intravenous group and the intratumor group by the random envelope method, 50 cases in each group. The patients were treated with NP regimen（2 cycles）, NP regimen（2 cycles） plus Aidi intravenous injection, or NP regimen（2 cycles） plus Aidi intratumor injection with thoracoscope, respectively for 6 weeks. The clinical efficacy was observed based on Response Evaluation Criteria in Solid Tumors（RECIST） rules, the expression of P-gp in the tumor tissue was tested before, 3 and 6 weeks after treatment, the safety was evaluated by monitoring the toxicity in the process of treatment, and the progressionfree survival（PFS） was measured. Results：Fifteen cases dropped out because of the irreconcilable conditions which had no relationship with the treatment, 4 in the control group, 5 in the intravenous group, and 6 in the intratumor group, respectively. Compared with the control group, the response rates（complete remission ＋ partial response） and the disease control rates（complete remission ＋ partial response ＋ stable disease） were significantly higher, the P-gp expressions were significantly decreased after 3 and 6 weeks of treatment, and the Kaplan-Meier survival curves of PFS were significantly longer in the intravenous and intratumor groups（P〈0.05 or P〈0.01）, and the intratumor group showed better effects than the intravenous group（P〈0.05 or P〈0.01）. Compared with the control group, the occurrences of rash, nausea and leukocytopenia were significantly decreased in the intravenous and intratumor groups（P〈0.05）, but without significant difference between the intravenous and intratumor groups（P〉0.05）. Conclusion：Aidi Injection not only improves the efficacy of NP regime, but also has the function of reducing adverse events and preventing against overexpression of P-gp induced by chemotherapy of NP regimen.展开更多
Objective To investigate the chemical constituents from Aidi Injection.Methods The chemical constituents were isolated by chromatography on Sephadex LH-20 gel columns and reverse phase semi-preparative HPLC repeatedly...Objective To investigate the chemical constituents from Aidi Injection.Methods The chemical constituents were isolated by chromatography on Sephadex LH-20 gel columns and reverse phase semi-preparative HPLC repeatedly.Their structures were identified by spectroscopic analysis(NMR and MS).Results Twenty-two compounds were isolated and identified to be 3-O-3′,4′-diacetyl-β-D-xylopyranosyl-6-O-β-D-glucopyranosyl- cycloastragenol(1),astragaloside IV(2),astragaloside II(3),astragaloside I(4),isoastragaloside I(5), acetylastragaloside I(6),ginsenosid Re(7),ginsenoside Rf(8),ginsenoside Rg1(9),ginsenoside Rb3(10), notoginsenoside R4(11),ginsenoside Rb1(12),ginsenoside Rc(13),ginsenoside Rb2(14),ginsenoside Rd(15), lucyoside H(16),3-O-β-D-glucopyranosyl(1→4)-β-D-glucopyranosyl(1→3)-α-L-rhamnopyranosyl(1→2)-α-L- arabinopyranosyl oleanolic acid 28-O-α-L-rhamnopyranosyl(1→4)-β-D-glucopyranosyl(1→6)-β-D-glucopyranoside (17),3-O-β-D-glucopyranosyl(1→3)-α-L-rhamnopyranosyl[β-D-glucopyranosyl-(1→4)]-(1→2)-α-L-arabinopyranosyl oleanolic acid 28-O-α-L-arabinopyranosyl(1→4)-β-D-glucopyranosyl(1→6)-β-D-glucopyranoside(18),syringin (19),elentheroside E(20),4-(1,2,3-trihydroxypropyl)-2,6-dimethoxyphenyl-1-O-β-D-glucopyranoside(21),and coniferin(22).Conclusion Compounds 1-6 are originated from Astragalus membranceus,compounds 7-18 are originated from Panax ginseng,and compounds 19-22 are originated from Acanthopanax senticosus by LC-MS analysis.Compound 1 is a new compound.展开更多
文摘Objective： To study the effects of Aidi Dripping Pills on immune functions of the tumor-bearing mouse on the basis of the previous experimental studies on its tumor-inhibiting and life-prolonging effects. Methods： By using the transplantation tumor mouse models, the effects of Aidi Dripping Pills on the lymphocyte transformation rate and the hemolysin formation in the Sis0 tumor-bearing mice, and on the phagocytic function of macrophages in the abdominal cavity of H22 tumor-bearing mice were investigated. Results： In the 2.25 g/kg and 1.125 g/kg Aidi Dripping Pills groups, the lymphocyte transformation rates in the Sis0 tumor-bearing mice were significantly higher than that of the control group （P〈0.01）. In all the Aidi Dripping Pills groups, HC50 significantly increased （P〈0.01 or P〈0.05）, carbon granular clearance significantly raised, and both the phagocytic index and phagocytic coefficient were significantly higher than those in the control group （P〈0.01 or P〈0.05）. Conclusion： The Aidi Dripping Pills can significantly increase the cellular immune function, the humoral immune function and the phagocytic function of the mononuclear- macrphages, so it may show anti-tumor effects by enhancing the function of the reticuloendothelial system.
基金supported by grants from Scientific Innovation Research of Shanghai Municipal Education Committee of China (No. 09YZ122)Doctoral Fund of Ministry of Education of China (20093107120010)E-Institutes of Shanghai Municipal Education Commission of China (E 03008)
文摘Objective: To investigate the effects of Aidi Injection (艾迪注射液 ADI) on the MicroRNAs (miRNA) expression profiles in human breast cancer cells and explore the potential targets of the cancer treatment. Methods: MCF-7 breast cancer cells were grown in RPMI 1640 medium supplemented with different concentrations of ADI. The inhibition of cell proliferation was measured by MTT assay. MCF-7 cells were treated by ADI with above 50% inhibiting concentration (IC50) for 48 h. The expression profiles of miRNA in ADI-treated and ADI-untreated MCF-7 cells were detected with miRNA microarray chips and the array data were verified by quantitative RT-PCR. MCF-7 cells were transiently transfected with miRNA mimics by liposome method. Potential mRNA targets were predicted by informatics analysis with TargetScan and PicTar software. Results: ADI significantly inhibited the proliferation of MCF-7 cells in a dose-dependent manner. The IC50 of ADI was 55.71 mg/mL after treatment for 48 h. The 60 mg/mL ADI was used as the therapeutic drug concentration. Microarray analysis identified 45 miRNAs that were up-regulated and 55 miRNAs that were down-regulated in response to ADI treatment. Many ADI-induced miRNAs were related to breast cancers. The microarray data were validated by qRT-PCR. Ectopic expression of 100 nmol/L mir-126 mimics significantly inhibited the proliferation of MCF-7 cells. The 12 potential target genes of mir-126 were predicted by both TargetScan and PicTar software. Conclusions: The miRNA may serve as therapeutic targets, and the modulation of miRNA expression is an important mechanism of ADI inhibiting breast cancer cell growth.
文摘OBJECTIVE: To conduct a Meta-analysis of studies on the effect of Aidi injectioncombined with chemotherapy versus chemotherapy alone in the treatment of gastric cancer(GC).METHODS: Nine electronic databases and six gray literature databases were comprehensively searcheduntil April 20,2013. Two reviewers independently selected and assessed included trialsaccording to the inclusion and exclusion criteria. The risk of bias tool from the Cochrane Handbook version 5.1.0was used to assess trial quality. All calculations were performed using Review Manager 5.0.RESULTS: Thirty-two studies including 1927 participants met the inclusion criteria,most of which were low quality. Compared with chemotherapy alone,Aidi injection plusthe same chemotherapy significantly improved the effective rate [OR = 1.52,95% CI(1.24,1.86),P < 0.0001],clinical beneficial rate [OR = 1.77,95% CI(1.33,2.36),P < 0.0001],and quality of life [OR = 3.02,95% CI(2.39,3.82),P <0.000 01]. There was a significant improvement in nausea and vomiting incidence [OR = 0.34,95%CI(0.24,0.47),P < 0.000 01],diarrhea [OR = 0.47,95%CI(0.33,0.69),P < 0.000 01],leukopenia( 3,0.51),P = 0.05],hemⅢ-ogⅣ)[OR = 0.34,95%CI(0.2lobin decrease(thromⅢ-boⅣ) [OR = 0.42,95%CI(0.18-1.00),P = 0.05],cytopenia(4],and Ⅲ-damⅣ) [OR = 0.46,95%CI(0.22,0.96),P = 0.0age to liver function [OR = 0.36,95%CI(0.24,0.54),P < 0.000 01].CONCLUSION: Aidi injection combined with chemotherapy significantly improved the clinical effect of chemotherapy,reducing the incidence of adverse events. Use of the CONSORT statement for randomized controlled trials is recommended for stricter reporting.
基金Supported by the Priority Academic Program Development of Jiangsu Higher Education Institutions(PAPD)SJZZ15_0119
文摘OBJECTIVE:To assess the efficacy and safety of Aidi injection plus transarterial chemoembolization(TACE)in patients with primary hepatic carcinoma.METHODS:A comprehensive research of seven electronic databases was performed for comparative studies evaluating Aidi injection combined with TACE for primary hepatic carcinoma until September 2016.Two authors independently extracted data and assessed the methodological quality of the included trials using the Cochrane risk of bias tool from the Cochrane Handbook version 5.1.0.Data was synthesized by using Rev Man 5.3 software.RESULTS:Forty-nine studies involving 3435 patients met the inclusion criteria,most of which were low methodological quality.Compared with TACE alone,Aidi injection plus TACE can significantly improve the efficiency rate[RR=1.33,95%CI(1.24,1.43),P<0.00001],clinical beneficial rate[RR=1.25,95%CI(1.17,1.33),P<0.00001],survival rate[6 months,RR=1.19,95%CI(1.09,1.29),P<0.0001],12 months,[RR=1.37,95%CI(1.24,1.52),P<0.00001],18 months,[RR=2.00,95%CI(1.26,3.20),P<0.004],24 months,[RR=1.44,95%CI(1.22,1.70),P<0.0001],36 months,[RR=1.50,95%CI(1.07,2.11),P=0.02<0.05],quality of life[RR=1.84,95%CI(1.64,2.05),P<0.00001]and immune function[CD3+,MD=11.12,95%CI(7.93,14.30),P<0.00001],CD4+,[MD=10.37,95%CI(7.29,13.45),P<0.00001],CD4+/CD8+,[MD=0.30,95%CI(0.07,0.53),P=0.01<0.05],NK,[MD=7.49,95%CI(6.64,8.34),P<0.00001].A significant improvement was also found in improvement of symptoms[RR=1.64,95%CI(1.38,1.94),P<0.00001],leukopenia[RR=0.60,95%CI(0.54,0.66),P<0.00001],thrombocytopenia[RR=0.46,95%CI(0.34,0.61),P<0.00001],nausea and vomiting incidence[RR=0.66,95%CI(0.54,0.81),P<0.0001),liver damage rate[RR=0.57,95%CI(0.42,0.77),P=0.0003<0.05),and kidney damage rate[RR=0.18,95%CI(0.05,0.68),P=0.01<0.05].CONCLUSION:The results suggested that Aidi injection plus TACE significantly improve the clinical effect of TACE,and reduce the incidence of adverse events.However,rigorous multicenter trials with larger size are warranted to further confirm the findings.
基金Medical science and technology innovation project of Nanjing military region(No.14ZX07)
文摘Objective:To explore the active ingredients and potential mechanism of Aidi injection in the treatment of hepatocellular carcinoma by network pharmacology.Methods:Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP)and Traditional Chinese Medicines Integrated Database(TCMID)were used to screen the active ingredients of four traditional Chinese medicines of Renshen,Huangqi,Ciwujia,and Banmao and corresponding potential targets.Screening of hepatocellular carcinoma-related targets through the Online Mendelian Inheritance in Man(OMIM)and GeneCards Suite(The Human Gene Database)database platforms.The drug and disease targets are merged to obtain the intersection,and the information is imported into Cytoscape 3.7.2 to construct a network diagram of the active ingredients of Aidi injection and related targets of hepatocellular carcinoma,and the topology analysis is performed.A protein-protein interaction(PPI)network was constructed and analyzed using the STRING online analysis platform.Uses the Database for Annotation,Visualization and Integrated Discovery(DAVID)to perform GO function enrichment analysis of targets and enrichment of KEGG pathways analysis.Results:A total of 33 potential active ingredients were screened from Aidi injection for treating hepatocellular carcinoma,including quercetin,kaempferol,beta-sitosterol,isorhamnetin and other important active ingredients.There are 106 potential targets for active ingredient action,6,677 disease-related targets,and 89 drug-disease common targets.Through the network diagram,it was found that the highest degree of target is PTGS1.In the PPI graph,a total of 87 nodes.Among them,the higher degree values include IL6,CASP3,VEGFA,MAPK8,JUN,EGFR,MYC,PTGS2 and FOS.A total of 60 related signal pathways were obtained by GO enrichment analysis.It mainly involves biological processes such as inhibiting abnormal proliferation and differentiation of hepatocellular carcinoma cells,inhibiting angiogenesis of hepatocellular carcinoma,regulating cell cycle and promoting apoptosis.KEGG pathway enrichment analysis screened a total of eight significantly different signal pathways.Among them,P53,VEGF,MAPK,Toll-like receptor,ErbB signaling pathways play an important role in treatment.Conclusion:This study initially revealed the potential mechanism of multi-component,multi-target and multi-pathway treatment of Aidi injection for hepatocellular carcinoma,and provided ideas for the subsequent verification of the molecular mechanism of Aidi injection for hepatocellular carcinoma.
文摘Objective： To evaluate the effects of Aidi injection on vinorelbine plus cisplatin （NP） chemotherapy for advanced non-small cell lung cancer （NSCLC）. Methods： Ninety eight patients with advanced NSCLC were randomized to receive either NP alone or NP plus Aidi injection every 3 weeks. The primary endpoint was overall survival; secondary endpoints included overall response rate, time to progression, and safety. Results： The median overall survival time was 11.6 months in NP plus Aidi-treated patients and 10.1 months in NP alone-treated ones, and 1- and 2-year survival rates were higher in the former （47% and 22%） than the latter （42% and 15%）. The overall response rates in Aidi injection plus NP-treated patients tended to be higher but not statistically significant compared with NP alone-treated ones. The occurrence rates of grades 3 or 4 toxicities, e.g. fatigue, nausea, vomiting, appetite loss, leucopenia, thrombocytopenia and anemia, were lower in Aidi injec- tion plus NP-treated patients than NP alone-treated ones, although not significantly different between them. Con^lusion：Aidi injection promotes NP chemotherapeutic effects, reduces the toxicities, and improves the patients＇ tolerance to chemotherapy as well. It may be an effective adjunct to chemotherapy in patients with NSCLC.
文摘Objective:To discuss the effect of Aidi injection-assisted intravenous chemotherapy on serum tumor markers and peripheral blood immune molecules in patients with colon cancer. Methods: 92 patients with colon cancer who were hospitalized in Deyang People's Hospital in Sichuan Province between October 2013 and October 2016 were collected and divided into the control group (n=50) who received intravenous chemotherapy alone and the observation group (n=42) who received Aidi injection-assisted intravenous chemotherapy after the therapies were reviewed. The differences in serum tumor markers and peripheral blood immune molecule contents before and after treatment were compared between two groups of patients.Results:Before treatment, differences in serum tumor marker levels and peripheral blood immune molecule levels were not statistically significant between two groups of patients. After treatment, serum tumor markers CEA, CA199, CA50, PTN and CCSA-2 levels of observation group were lower than those of control group, peripheral blood Th1/Th2 cytokines IL-2 and IFN-γ levels were higher than those of control group while IL-4 and IL-10 levels were lower than those of control group, and peripheral blood Th17 cytokines IL-17A and IL-22 levels were lower than those of control group.Conclusion: Aidi injection-assisted intravenous chemotherapy can effectively reduce the serum tumor marker contents and optimize the immune molecule levels in patients with colon cancer.
基金Natural Science Foundation of Inner Mongolia No:2014MS1825.
文摘Objective:To study the effect of Aidi injection combined with FOLFOX4 chemotherapy on tumor stem cell characteristics and antitumor immune response in patients with advanced colon cancer.Methods:Patients with advanced colon cancer who received chemotherapy in our hospital between May 2013 and June 2016 were selected and randomly divided into the combined chemotherapy group who received Aidi injection combined with FOLFOX4 chemotherapy and the FOLFOX4 group who received FOLFOX4 chemotherapy alone. After chemotherapy, the serum was collected to determine the levels of tumor markers, tumor lesions were collected to determine the expression of tumor stem cell markers and immune cell markers, and peripheral blood mononuclear cells were collected to determine the expression of immune cell markers.Results:After 2 and 4 cycles of treatment, serum CEA, CA199, CCSA-3 and CCSA-4 levels of combined chemotherapy group were significantly lower than those of FOLFOX4 group, and the mean fluorescence intensity of CD3, CD4, CD8, CD16 and CD56 in peripheral blood mononuclear cells were significantly higher than those of FOLFOX4 group;after four cycles of chemotherapy, CD133, Musashi-1, Piwil2, Nanog and Sox-2 protein content in tumor lesions were significantly lower than those of FOLFOX4 group, and the mean fluorescence intensity of CD3, CD4, CD8, CD16 and CD56 were significantly higher than those of FOLFOX4 group.Conclusion: Aidi injection combined with FOLFOX4 chemotherapy treatment of advanced colon cancer will help reduce the tumor load, inhibit tumor stem cell characteristics and enhance antitumor immune response.
文摘Objective: To explore the influence of Aidi injection combined with paclitaxel and platinum drugs on malignant molecule expression in malignant ascites of patients with advanced gastric cancer. Methods: A total of 80 patients with advanced gastric cancer complicated by malignant ascites who were treated in the hospital between January 2015 and December 2016 were divided into control group and observation group by random number table, each with 40 cases. Control group were treated with paclitaxel and platinum drugs, and observation group were treated with Aidi injection combined with paclitaxel and platinum drugs. The differences in the malignant molecule expression in malignant ascites were compared between the two groups of patients before and after treatment. Results: Before treatment, the proliferation, invasion and autophagy gene expression in malignant ascites were not statistically different between the two groups of patients. 1 week after treatment, EZH2, I2PP2A, Gal-1, HPA-1, MTA1, TROP2, BNIP3 and LC3 mRNA expression in malignant ascites of both groups of patients were lower than those before treatment while PTPN13, TRIM28, SOX7, Syndecan-1 and Beclin1 mRNA expression were higher than those before treatment, and EZH2, I2PP2A, Gal-1, HPA-1, MTA1, TROP2, BNIP3 and LC3 mRNA expression in malignant ascites of observation group were lower than those of control group while PTPN13, TRIM28, SOX7, Syndecan-1 and Beclin1 mRNA expression were higher than those of control group. Conclusion: Aidi injection combined with paclitaxel and platinum drugs can effectively inhibit the gastric cancer cell proliferation and invasion, and regulate cell autophagy activity in the malignant ascites of patients with advanced gastric cancer.
文摘目的探讨课题组前期从艾迪注射液(Aidi injection,AD)中筛选出的12个Q-markers(6个抗肿瘤,6个心脏毒性保护)是否对AD原方的2种治疗作用具有代表性。方法基于前期工作基础,将这2种作用的Q-markers分别按照AD原方相同的浓度配制成不同的抗肿瘤Q-markers组合物和不同的心脏毒性保护作用Q-markers组合物,对比AD原方,在Huh7、HUVEC和H9c2细胞上,采用常规CCK8法分别评价组合物的抗肿瘤作用,以及组合物的心脏毒性保护作用。同时采用UHPLC-Q-Exactive Plus Orbitrap HRMS进行细胞代谢组学研究,分析细胞代谢谱,结合PLS-DA模型计算分析平均距离值,评价抗肿瘤Q-markers组合物与AD原方的相似性,结合PLS-DA模型计算分析相对平均距离值,评价心脏毒性保护作用Q-markers组合物与AD原方的相似性。结果CCK8和细胞代谢组学实验结果趋势基本一致,显示5个抗肿瘤Q-markers组合物(斑蝥素、人参皂苷Re、人参皂苷Rb1、黄芪皂苷Ⅱ和人参皂苷Rg2)优于6个抗肿瘤Q-markers组合物和AD原方,5个心脏毒性保护作用Q-markers组合物(刺五加苷E、紫丁香苷、人参皂苷Rd、毛蕊异黄酮葡萄糖苷和壬二酸)优于6个Q-markers组合物和AD原方。结论斑蝥素、人参皂苷Re、人参皂苷Rb1、黄芪皂苷Ⅱ和人参皂苷Rg2可作为AD抗肿瘤作用的潜在Q-markers,刺五加苷E、紫丁香苷、人参皂苷Rd、毛蕊异黄酮葡萄糖苷和壬二酸可作为AD心脏毒性保护作用的潜在Q-markers,它们具有同等或优于原方的抗肿瘤和心脏毒性保护作用效果。
基金Supported by Guangxi Chinese Medicine Science and Technology Major Projects(No.GZKZ-Z1103)International Cooperation Projects of the Ministry of Science and Technology(No.S2012ZR0128)
文摘Objective: To evaluate the effects of Aidi Injection(艾迪注射液, AD) in combination with Western medical therapies(WMT) in patients with primary liver cancer(PLC). Methods: Randomized controlled trials(RCTs) comparing AD plus WMT with WMT alone were retrieved from inception to March 2013 by retrieving the literature database thoroughly and systematically. The extracted data from included studies were analyzed and synthesized by Review Manager 5.2 software. The Cochrane risk of bias tool was used to assess the quality of included studies, and Begg’s and Egger’s tests were used to evaluate the potential presence of publication bias. The studies were divided into 7 separate subgroups in terms of quality of life(QOL), recent chemotherapy and the incidence of leukocyte reduction. The subgroup analysis was applied to assess the heterogeneity between included researches, and the sensitivity analysis was used to weigh the stability of studies. Results: Twenty-four RCTs were included in this study. Compared with WMT used alone, AD as additional intervention was more effective on improving QOL(P<0.01), increasing short-term efficacy(P<0.01), prolonging life(P<0.05 or P<0.01), relieving clinical symptoms(P<0.01), and reducing adverse events(e.g. reduce white blood cell counts, P=0.002;reduce in platelet counts, P<0.01). Subgroup analysis showed that the hepatic artery interventions with AD was superior in improving QOL(P<0.01) and enhancing short-term response rates(P=0.007) and reducing white blood cell counts(P=0.0004) than hepatic artery interventions alone(P<0.01). The chemoembolization plus AD or the chemotherapy plus AD were both better than chemoembolization or the chemotherapy alone in improving the QOL and short-term response rate(P<0.05 or P<0.01). Conclusions: AD in combination with WMT improves QOL in patients with PLC. Considering the inherent limitations of the included studies, further well-designed, rigorously performed, high-quality, and double-blinded RCTs with large sample sizes are needed.
文摘Background： The aim of this study was to assess the efficacy and safety of vinorelbine and cisplatin （NP chemotherapy） alone or in combination with Aidi injection for the treatment of advanced nonsmall cell lung cancer （NSCLC）. Methods： Pertinent publications were identified in PubMed, EMBASE, Cochrane Library, CNKI, CQVIR and Wanfang databases, up to December 8, 2015. After quality assessment of all included randomized controlled trials evaluating Aidi injection combined with NP chemotherapy for the treatment of advanced NSCLC, a meta-analysis was performed by Review Manager 5.2 and STATA 12.0 for statistical analyses. Results： Twelve studies including 509 and 503 cases in the experimental and control groups, respectively, were finally analyzed. The meta-analysis revealed that when cisplatin dose ranging from 20 to 40 mg/m2, combination of Aidi injection and NP chemotherapy was statistically different compared with NP chemotherapy alone in enhancing efficiency （relative risk [RR] = 1.24, 95% confidence interval [C/] [ 1.05-1.47], P = 0.010） and reducing the incidence of Grade II or above nausea and vomiting （RR = 0.49, 95% CI [0.30-0.80], P = 0.005）. Meanwhile, with cisplatin ranging from 80 to 120 mg/m2, no significant differences in efficiency （RR = 1.11, 95% CI [0.87- 1.42], P = 0.390） and Grade II or above nausea and vomiting （RR = 0.88, 95% CI [0.71-1.10], P = 0.260） were obtained. In addition, Aidi injection combined with NP chemotherapy was superior to NP chemotherapy alone in improving the quality of life, alleviating Grade II or above leukopenia and thrombocytopenia. Conclusions： Aidi injection combined with NP chemotherapy can enhance efficiency, improve the quality of life, and decrease adverse effects in patients with advanced NSCLC.
文摘Objective： To study the effect of Aidi Injection （艾迪注射液,ADI） applied in the bronchial artery infused （BAI） neo-adjuvant chemotherapy for stage ⅢA non-small cell lung cancer （NSCLC） before surgical operation.Methods： The 60 patients with NSCLC stage ⅢA underwent two courses BAI chemotherapy before tumor incision were assigned to two groups,the treatment and the control groups,using a random number table,30 in each group.ADI （100 mL） was given to the patients in the treatment group by adding into 500 mL of 5% glucose injection for intravenous dripping once daily,starting from 3 days before each course of chemotherapy,and it lasted for 14 successive days,so a total of 28 days of administration was completed.The therapeutic effectiveness and the adverse reaction that occurred were observed,and the levels of T-lymphocyte subsets,natural killer cell activity,and interleukin-2 in peripheral blood were measured before and after the treatment.Results： The effective rate in the treatment group was higher than that in the control group （70.0% vs.56.7%,P〈0.05）.Moreover,as compared with the control group,the adverse reaction that occurred in the treatment group was less and mild,especially in terms of bone marrow suppression and liver function damage （P〈0.05）.Cellular immune function was suppressed in NSCLC patients,but after treatment,it ameliorated significantly in the treatment group,showing significant difference as compared with that in the control group （P〈0.05）.Conclusion： ADI was an ideal auxiliary drug for the patients in stage ⅢA NSCLC received BAI neo-chemotherapy before surgical operation;it could enhance the effectiveness of chemotherapy,ameliorate the adverse reaction and elevate patients＇ cellular immune function;therefore,it is worthy for spreading in clinical practice.
基金Supported by the 2011 National Key Specialty Construction of Clinical Projects of China,Science and Technology Projects of Traditional Chinese Medicine Bureau in Jiangsu Province of China(No.LB13042)
文摘Objective：To investigate the efficacy of Aidi Injection（艾迪注射液） on overexpression of P-glycoprotein（P-gp） induced by vinorelbine and cisplatin（NP） regimen in patients with non-small cell lung cancer（NSCLC）, and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. Methods：Totally 150 patients with NSCLC were randomly assigned to the control group, the intravenous group and the intratumor group by the random envelope method, 50 cases in each group. The patients were treated with NP regimen（2 cycles）, NP regimen（2 cycles） plus Aidi intravenous injection, or NP regimen（2 cycles） plus Aidi intratumor injection with thoracoscope, respectively for 6 weeks. The clinical efficacy was observed based on Response Evaluation Criteria in Solid Tumors（RECIST） rules, the expression of P-gp in the tumor tissue was tested before, 3 and 6 weeks after treatment, the safety was evaluated by monitoring the toxicity in the process of treatment, and the progressionfree survival（PFS） was measured. Results：Fifteen cases dropped out because of the irreconcilable conditions which had no relationship with the treatment, 4 in the control group, 5 in the intravenous group, and 6 in the intratumor group, respectively. Compared with the control group, the response rates（complete remission ＋ partial response） and the disease control rates（complete remission ＋ partial response ＋ stable disease） were significantly higher, the P-gp expressions were significantly decreased after 3 and 6 weeks of treatment, and the Kaplan-Meier survival curves of PFS were significantly longer in the intravenous and intratumor groups（P〈0.05 or P〈0.01）, and the intratumor group showed better effects than the intravenous group（P〈0.05 or P〈0.01）. Compared with the control group, the occurrences of rash, nausea and leukocytopenia were significantly decreased in the intravenous and intratumor groups（P〈0.05）, but without significant difference between the intravenous and intratumor groups（P〉0.05）. Conclusion：Aidi Injection not only improves the efficacy of NP regime, but also has the function of reducing adverse events and preventing against overexpression of P-gp induced by chemotherapy of NP regimen.
基金National Technology Research Program for Creating New Drugs (2009ZX09308-003 and 2011ZX09201-201-16)
文摘Objective To investigate the chemical constituents from Aidi Injection.Methods The chemical constituents were isolated by chromatography on Sephadex LH-20 gel columns and reverse phase semi-preparative HPLC repeatedly.Their structures were identified by spectroscopic analysis(NMR and MS).Results Twenty-two compounds were isolated and identified to be 3-O-3′,4′-diacetyl-β-D-xylopyranosyl-6-O-β-D-glucopyranosyl- cycloastragenol(1),astragaloside IV(2),astragaloside II(3),astragaloside I(4),isoastragaloside I(5), acetylastragaloside I(6),ginsenosid Re(7),ginsenoside Rf(8),ginsenoside Rg1(9),ginsenoside Rb3(10), notoginsenoside R4(11),ginsenoside Rb1(12),ginsenoside Rc(13),ginsenoside Rb2(14),ginsenoside Rd(15), lucyoside H(16),3-O-β-D-glucopyranosyl(1→4)-β-D-glucopyranosyl(1→3)-α-L-rhamnopyranosyl(1→2)-α-L- arabinopyranosyl oleanolic acid 28-O-α-L-rhamnopyranosyl(1→4)-β-D-glucopyranosyl(1→6)-β-D-glucopyranoside (17),3-O-β-D-glucopyranosyl(1→3)-α-L-rhamnopyranosyl[β-D-glucopyranosyl-(1→4)]-(1→2)-α-L-arabinopyranosyl oleanolic acid 28-O-α-L-arabinopyranosyl(1→4)-β-D-glucopyranosyl(1→6)-β-D-glucopyranoside(18),syringin (19),elentheroside E(20),4-(1,2,3-trihydroxypropyl)-2,6-dimethoxyphenyl-1-O-β-D-glucopyranoside(21),and coniferin(22).Conclusion Compounds 1-6 are originated from Astragalus membranceus,compounds 7-18 are originated from Panax ginseng,and compounds 19-22 are originated from Acanthopanax senticosus by LC-MS analysis.Compound 1 is a new compound.
